- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07703917
TENS for Postpartum Uterine Pain During Breastfeeding
Transcutaneous Electrical Nerve Stimulation for Treating Postpartum Uterine Pain During Breastfeeding in Multiparous Women: a Randomized Controlled Trial
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This randomized, controlled, parallel-group clinical trial will evaluate the efficacy and safety of Transcutaneous Electrical Nerve Stimulation (TENS) as a non-pharmacological intervention for reducing oxytocin-induced postpartum uterine contractions during breastfeeding. The study cohort consists of 124 eligible multiparous women (2 or more previous births) admitted to the Department of Obstetrics and Gynecology at Holy Family Hospital in Nazareth, Israel, within 48 hours following a term, singleton, vaginal delivery. Following the acquisition of written informed consent, participants will be randomized at a 1:1 ratio into either the TENS study group or the standard care control group. The experimental protocol will be integrated into two consecutive breastfeeding sessions. Body positioning will be strictly standardized across both cohorts. TENS Study Group (Intervention): Prior to the second consecutive breastfeeding session, four conductive gel electrodes will be affixed to the participant. Two electrodes will be positioned bilaterally over the lower abdomen, directly overlying the uterus. The remaining two electrodes will be placed in parallel in the S2-S4 dermatomal region to target the spinal nerve pathways receiving nociceptive afferent input from the uterus and cervix. Active stimulation will commence a few minutes prior to breastfeeding and continue for the entire duration of the feed. The TENS device will deliver a 100-Hz current and 75 msec pulse for 40 min, using 20-60 milliamps of intensity.
To establish a baseline pain score, the first evaluated breastfeeding session for this group will be conducted without TENS application, followed by active TENS during the second session. Control Group Protocol: Participants assigned to the control group will receive standard postpartum care and will undergo the identical data collection schedule across two consecutive breastfeeding sessions, but without any TENS electrode placement or electrical stimulation.
For both study arms, pharmacological analgesia will remain accessible as needed per existing institutional department protocols, and all instances of medication administration (including specific agent, timing, and dosage) will be precisely documented. Uterine pain scores will be captured across both groups at three identical time points during each of the two consecutive breastfeeding sessions: Maternal discomfort associated directly with the physical application or sensation of the TENS unit will be separately quantified.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Marwa Bayatra, MD
- Numero di telefono: 97246508900
- Email: bayatra7@gmail.com
Backup dei contatti dello studio
- Nome: RAED SALIM, PROF
- Numero di telefono: 97246508900
- Email: r.salim@hfhosp.org
Luoghi di studio
-
-
-
Nazareth, Israele
- Reclutamento
- Holy Family Hospital
-
Contatto:
- Raed
- Email: r.salim@hfhosp.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Maternal Age above 18
- Term delivery (37 weeks or more)
- Vaginal delivery within the past 48 hours.
- Multiparous women (2 or more previous births)
- Delivery of a singleton
- Have the well to breastfeed
Exclusion Criteria:
- Contraindication to TENS (pacemaker, epilepsy, active infection, uncontrolled hyper / hypotension.)
- Chronic analgesia use
- Severe complications requiring intervention (severe PPH) or intensive care
- Skin lesions, infections, or scars at proposed electrode sites
- Neonatal intensive care unit admission
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: TENS Group
This arm is receiving the active clinical intervention being evaluated in the study (the TENS device).
Pain scores will be assessed during two consecutive breastfeeding sessions.
The first with, and the second without TENS.
|
Bilateral application of four skin electrodes using conductive gel.
Two electrodes will be placed on the lower abdomen over the uterus, and two will be placed in parallel in the S2-S4 sacral region.
The digital sensory-motor TENS device will be programmed to generate a 100-Hz current and 75 msec pulse for 40 min, using 20-60 mA of intensity.
Stimulation begins a few minutes before breastfeeding and continues throughout the 40-minute session.
|
|
Nessun intervento: No-TENS Control Group
Participants assigned to this control group will receive standard postpartum care only, without any TENS application.
Pain scores will be assessed during two consecutive breastfeeding sessions within the first 48 hours postpartum to serve as a comparative baseline against the intervention group.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Peak VAS pain score during breastfeeding in the second session
Lasso di tempo: During the second breastfeeding session, within the first 48 hours postpartum
|
The maximum VAS score recorded will be compared between groups.
Postpartum uterine pain during breastfeeding will be evaluated using a standard Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).
|
During the second breastfeeding session, within the first 48 hours postpartum
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Consumption of Pharmacological Analgesics
Lasso di tempo: First 48 hours postpartum
|
Total dosage (mg) of pain relief medications consumed by the participant within the first 48 hours postpartum.
|
First 48 hours postpartum
|
|
Peak VAS pain score during breastfeeding in the second compared with the first sessions.
Lasso di tempo: During two consecutive breastfeeding sessions within the first 48 hours postpartum
|
The maximum VAS score in the first and second session will be recorded and compared within the same group.
Postpartum uterine pain during breastfeeding will be evaluated using a standard Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).
|
During two consecutive breastfeeding sessions within the first 48 hours postpartum
|
|
Duration of breastfeeding sessions.
Lasso di tempo: In the two consecutive breastfeeding sessions within the first 48 hours postpartum
|
The time, in minutes, that the woman is able to continue breastfeeding.
|
In the two consecutive breastfeeding sessions within the first 48 hours postpartum
|
|
Adverse effects related to TENS use
Lasso di tempo: During the second session, within the first 48 hours postpartum
|
Local adverse effects related to TENS in the intervention group.
|
During the second session, within the first 48 hours postpartum
|
|
Maternal discomfort
Lasso di tempo: First 48 hours postpartum
|
The women will also be asked to estimate the discomfort of the TENS use using a 5-point verbal scale from no discomfort (0) to worst possible discomfort (5).
|
First 48 hours postpartum
|
|
Formula use
Lasso di tempo: First 48 hours postpartum
|
Use of any infant formula in addition to breastfeeding
|
First 48 hours postpartum
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Raed Salim, M.D., Holy Family Hospital, Nazareth, Israel
Pubblicazioni e link utili
Pubblicazioni generali
- McKay TB, Priyadarsini S, Karamichos D. Mechanisms of Collagen Crosslinking in Diabetes and Keratoconus. Cells. 2019 Oct 11;8(10):1239. doi: 10.3390/cells8101239.
- Alswied A, Chen LN, West-Mitchell KA. Longitudinal assessment of erythrogram parameters in response to granulocytapheresis frequency: A sex-based analysis. Vox Sang. 2025 Mar;120(3):268-276. doi: 10.1111/vox.13788. Epub 2025 Jan 1.
- Vera Pingitore E, Hebert EM, Sesma F, Nader-Macias ME. Influence of vitamins and osmolites on growth and bacteriocin production by Lactobacillus salivarius CRL 1328 in a chemically defined medium. Can J Microbiol. 2009 Mar;55(3):304-10. doi: 10.1139/w08-092.
- Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand. 2007;86(2):185-90. doi: 10.1080/00016340601110770.
- Radhakrishnan R, Moore SA, Sluka KA. Unilateral carrageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. Pain. 2003 Aug;104(3):567-577. doi: 10.1016/S0304-3959(03)00114-3.
- Silbert BI, Lam SJ, Henderson RD, Lake FR. Students as teachers. Med J Aust. 2013 Dec 16;199(11):757. doi: 10.5694/mja13.11353. No abstract available.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- HFH-321/2026
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .